{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:33Z","timestamp":1777858173497,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2004,6]]},"abstract":"\n The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, has been suggested. Risperidone has been shown to inhibit the delayed rectifier leading to lengthening of cardiac repolarization. The heart-rate corrected QT (QTc) interval lengthening has been reported in psychiatric patients receiving risperidone under steady-state conditions. CYP2D6 is involved in the metabolism of risperidone to 9-hydroxy (OH)-risperidone. CYP2C9 enzyme is also involved in the metabolism of several psychotropic drugs, although there are no data about its implication in risperidone metabolism. The present study aimed to evaluate the influence of\n CYP2D6<\/jats:italic>\n and\n CYP2C9<\/jats:italic>\n genotypes, and plasma concentrations of risperidone and 9-OH-risperidone on the QTc interval in patients under steady-state conditions. The relevance of\n CYP2D6<\/jats:italic>\n and\n CYP2C9<\/jats:italic>\n genotypes on risperidone metabolism was also analysed. Thirty-five White European psychiatric patients receiving risperidone monotherapy were studied. QTc interval was longer (\n p<\/jats:italic>\n < 0.05) in subjects with one active\n CYP2D6<\/jats:italic>\n gene compared to those with two. The number of\n CYP2D6<\/jats:italic>\n active genes was related to the dose-corrected plasma concentration of risperidone (\n p<\/jats:italic>\n < 0.05), the active moiety (risperidone plus 9-OH-risperidone) (\n p<\/jats:italic>\n < 0.05) and the risperidone\/9-OH-risperidone ratio (\n p<\/jats:italic>\n < 0.05).\n CYP2C9<\/jats:italic>\n genotypes were not related to plasma concentrations of risperidone or 9-OH-risperidone, nor QTc interval. The results suggest that\n CYP2D6<\/jats:italic>\n , but not\n CYP2C9<\/jats:italic>\n , may be related to QTc lengthening during treatment with risperidone. The effect of the\n CYP2D6<\/jats:italic>\n genotype in risperidone metabolism is also shown.\n <\/jats:p>","DOI":"10.1177\/0269881104042618","type":"journal-article","created":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T22:12:53Z","timestamp":1088719973000},"page":"189-193","source":"Crossref","is-referenced-by-count":67,"title":["QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations"],"prefix":"10.1177","volume":"18","author":[{"given":"Adri\u00e1n","family":"Llerena","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Psychiatry, Faculty of Medicine, University of Extremadura, Badajoz, Spain, Unit of Research and Clinical Psychopharmacology at M\u00e9rida Psychiatric Hospital, M\u00e9rida, Spain and University of Beira Interior, Covilh\u00e3, Portugal.,"}]},{"given":"Roland","family":"Berecz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Psychiatry, Faculty of Medicine, University of Extremadura, Badajoz, Spain."}]},{"given":"Pedro","family":"Dorado","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Psychiatry, Faculty of Medicine, University of Extremadura, Badajoz, Spain and University of Beira Interior, Covilh\u00e3, Portugal."}]},{"given":"Alfredo","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Psychiatry, Faculty of Medicine, University of Extremadura, Badajoz, Spain and Unit of Research and Clinical Psychopharmacology at M\u00e9rida Psychiatric Hospital, M\u00e9rida, Spain."}]}],"member":"179","published-online":{"date-parts":[[2004,6]]},"reference":[{"key":"e_1_2_1_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90708-O"},{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-36389"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0709"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(05)80421-4"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0588-0"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200306000-00016"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005334"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01626-6"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01499.x"},{"key":"e_1_2_1_10_1","first-page":"62","article-title":"Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia","volume":"26","author":"Gury C","year":"2000","unstructured":"Gury C , Canceil O , Iaria P (2000) Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia . Encephale 26: 62-72","journal-title":"Encephale"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2249"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00119-X"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.146"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00004"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-31517"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02074-5"},{"key":"e_1_2_1_16_1","first-page":"305","article-title":"A case of risperidone overdose in early schizophrenia: a review of potential complications","volume":"23","author":"Kopala L C","year":"1998","unstructured":"Kopala L C , Day C , Dillman B , Gardner D (1998) A case of risperidone overdose in early schizophrenia: a review of potential complications . J Psychiatry Neurosci 23: 305-308","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200204000-00010"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190261"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200112000-00004"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0452-7"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600411"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00661-X"},{"key":"e_1_2_1_23_1","first-page":"5","article-title":"Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"Leysen J E","year":"1994","unstructured":"Leysen J E , Janssen P M , Megens A A , Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity . J Clin Psychiatry 55 (Suppl): 5-12","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-6757(96)90026-1"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-002-0595-1"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)08211-X"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100712"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.12.1161"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02035-3"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.4.1516"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051171"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200208000-00014"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000489"},{"key":"e_1_2_1_34_1","unstructured":"Study 054. Briefing document for Zeldox capsules (ziprasidone HCl) FDA Psychopharmacological Drugs Advisory Committee 19 July 2000 [available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3619b1a.pdf; accessed 12 February 2003]"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0705"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881104042618","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881104042618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:56Z","timestamp":1777507736000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881104042618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1177\/0269881104042618"],"URL":"https:\/\/doi.org\/10.1177\/0269881104042618","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}